Product Description
Atorvastatin is used together with diet, weight loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease. Atorvastatin is also used to decrease the amount of fatty substances such as low-density lipoprotein (LDL) cholesterol ('bad cholesterol') and triglycerides in the blood and to increase the amount of high-density lipoprotein (HDL) cholesterol ('good cholesterol') in the blood.
Mechanisms of Action: HMG-CoA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Korea, Netherlands, Nigeria, Norway, Poland, Portugal, Russia, Spain, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 29
Highest Development Phases
Phase 3: Acute Pain|Breast Cancer|Dyslipidemia|Hypercholesterolemia|Hypertension|IgA Nephropathy|Obesity|Other|Prostate Cancer|Tuberculosis, Pulmonary
Phase 2: Hepatitis A|Hepatitis B|Hypertension, Portal|Inflammation|Kidney Cancer|Liver Cirrhosis|Ovarian Cancer|Triple Negative Breast Cancer
Phase 1: Conduct Disorder|Healthy Volunteers|Hyperlipidemia|Overweight|Pregnancy Outcomes|Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-515404-39-00 | P3 |
Unknown Status |
Breast Cancer |
2045-01-01 |
|
| 417-201-00012 | P3 |
Unknown Status |
IgA Nephropathy |
2029-02-28 |
|
| 2016-004774-17 | P3 |
Active, not recruiting |
Prostate Cancer |
2028-08-16 |
|
| ESTO2 | P3 |
Recruiting |
Prostate Cancer |
2025-12-31 |